Oncology Nursing Update: Multiple Myeloma — An Interview with Dr Beth Faiman on CAR T-Cell Therapy

Featuring an interview with Dr Beth Faiman, including the following topics:

• Clinical practice background and historical view of treatment for multiple myeloma (MM) (0:00)
• Fundamental principles associated with chimeric antigen receptor (CAR) T-cell therapy (7:19)
• Sequencing of CAR T-cell therapy and bispecific antibodies in the MM treatment landscape (9:00)
• Patient eligibility to receive CAR T-cell therapy (13:23)
• Differentiating among approved CAR T-cell therapies for MM (18:18)
• Durability of responses to CAR T-cell therapy for MM (24:01)
• Neurotoxicity with CAR T-cell therapies for MM (26:26)
• Minimal residual disease monitoring in MM (29:39)
• Support systems for the management of toxicities associated with CAR T-cell therapy (35:10)
• Patients with MM experiencing durable responses to CAR T-cell therapy (43:11)

NCPD information and select publications